Nesiritide
Natrecor (nesiritide) is a protein pharmaceutical. Nesiritide was first approved as Natrecor on 2001-08-10. It is used to treat paroxysmal dyspnea in the USA. It is known to target atrial natriuretic peptide receptor 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| paroxysmal dyspnea | — | D004418 | I50.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2325 | Injection, nesiritide, 0.1 mg |
Clinical
Clinical Trials
451 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | 9 | 22 | 17 | 28 | 116 | 185 |
| Hypertension | D006973 | EFO_0000537 | I10 | 4 | 3 | — | 7 | 20 | 32 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | 1 | 2 | 8 | 2 | 14 | 25 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | 1 | 1 | 1 | 20 | 24 |
| Renal insufficiency | D051437 | — | N19 | 3 | 6 | 7 | 1 | 7 | 22 |
| Dyspnea | D004417 | — | R06.0 | — | 1 | 2 | 4 | 11 | 18 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | 1 | 2 | 13 | 16 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | — | 6 | 10 | 16 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 2 | 1 | 2 | 10 | 15 |
| Coronary artery disease | D003324 | — | I25.1 | — | 1 | 1 | 2 | 11 | 14 |
Show 40 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial infarction | D009203 | EFO_0000612 | I21 | 1 | 2 | 1 | — | 14 | 18 |
| Acute kidney injury | D058186 | — | N17 | 1 | 2 | 1 | — | 7 | 10 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 1 | — | 8 | 9 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | — | 6 | 7 |
| Systolic heart failure | D054143 | EFO_1001207 | I50.20 | — | 1 | 1 | — | 2 | 4 |
| Duchenne muscular dystrophy | D020388 | EFO_0000429 | — | — | 1 | 1 | — | 3 | 4 |
| Cardiopulmonary bypass | D002315 | — | — | 1 | 2 | 1 | — | 1 | 4 |
| Death | D003643 | PATO_0001422 | — | — | — | 1 | — | 3 | 4 |
| Coronary artery bypass | D001026 | EFO_0003776 | — | — | 1 | 1 | — | 1 | 3 |
| Muscular dystrophies | D009136 | EFO_0000757 | G71.0 | — | 1 | 1 | — | 2 | 3 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infarction | D007238 | EFO_0009463 | — | 1 | 1 | — | — | 10 | 12 |
| Congenital heart defects | D006330 | — | Q24.9 | 1 | 2 | — | — | 7 | 9 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 1 | — | — | 2 | 3 |
| Systolic murmurs | D054160 | — | R01.1 | — | 1 | — | — | 2 | 3 |
| Obstructive lung diseases | D008173 | — | — | — | 1 | — | — | 2 | 3 |
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | 1 | — | — | 2 | 3 |
| Unstable angina | D000789 | EFO_1000985 | I20.0 | — | 1 | — | — | 1 | 2 |
| Asymptomatic diseases | D058070 | — | — | 1 | 1 | — | — | — | 1 |
| Heart transplantation | D016027 | EFO_0010673 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | 2 | — | — | — | — | 2 |
| Carcinoma | D002277 | — | C80.0 | 1 | — | — | — | 1 | 2 |
| Hyperinsulinism | D006946 | — | E16.1 | 1 | — | — | — | — | 1 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
| Hypophosphatemia | D017674 | HP_0002148 | — | 1 | — | — | — | — | 1 |
| Cardiac resynchronization therapy | D058406 | — | — | 1 | — | — | — | — | 1 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiotoxicity | D066126 | EFO_1001482 | — | — | — | — | — | 12 | 12 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 11 | 11 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | — | — | 10 | 10 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 8 | 8 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 8 | 8 |
| Toxemia | D014115 | — | — | — | — | — | — | 8 | 8 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 7 | 7 |
| Pathologic constriction | D003251 | — | — | — | — | — | — | 7 | 7 |
| Emergencies | D004630 | — | — | — | — | — | — | 6 | 6 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 5 | 5 |
Show 202 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nesiritide |
| INN | nesiritide |
| Description | Natriuretic peptides B [Precursor] |
| Classification | Protein |
| Drug class | peptides: atrial natriuretic type substances |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201668 |
| ChEBI ID | — |
| PubChem CID | 16134381 |
| DrugBank | DB04899 |
| UNII ID | P7WI8UL647 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
NPR1
NPR1
Organism
Homo sapiens
Gene name
NPR1
Gene synonyms
ANPRA
NCBI Gene ID
Protein name
atrial natriuretic peptide receptor 1
Protein synonyms
ANP-A, ANPR-A, Atrial natriuretic peptide receptor type A, atrionatriuretic peptide receptor A, GC-A, Guanylate cyclase A, natriuretic peptide A type receptor, natriuretic peptide receptor A, natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic peptide receptor A), NPR-A, testicular tissue protein Li 20
Uniprot ID
Mouse ortholog
Npr1 (18160)
atrial natriuretic peptide receptor 1 (P18293)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 48,433 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
363 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use